Cargando…

Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis

BACKGROUND: Based on the mechanism of action, combining somatostatin analogues (SSAs) with mTOR inhibitors or antiangiogenic agents may provide synergistic effects for the treatment of patients with neuroendocrine tumours (NETs). Herein, we investigate the use of these treatment combinations in clin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Capdevila, Jaume, Sevilla, Isabel, Alonso, Vicente, Antón Aparicio, Luís, Jiménez Fonseca, Paula, Grande, Enrique, Reina, Juan José, Manzano, José Luís, Alonso Lájara, Juan Domingo, Barriuso, Jorge, Castellano, Daniel, Medina, Javier, López, Carlos, Segura, Ángel, Carrera, Sergio, Crespo, Guillermo, Fuster, José, Munarriz, Javier, García Alfonso, Pilar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490650/ https://www.ncbi.nlm.nih.gov/pubmed/26138480 http://dx.doi.org/10.1186/s12885-015-1512-6

Ejemplares similares

Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review
por: Grande, Enrique, et al.
Publicado: (2019)

Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib
por: Jiménez-Fonseca, Paula, et al.
Publicado: (2018)

Real world use of lanreotide in neuroendocrine tumors
por: Siddiqui, Zeba, et al.
Publicado: (2023)

Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study
por: Martín-Richard, Marta, et al.
Publicado: (2013)

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study
por: Caplin, Martyn E, et al.
Publicado: (2016)

Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors
por: Wolin, Edward M., et al.
Publicado: (2016)

Clinical utility of lanreotide Autogel(®) in gastroenteropancreatic neuroendocrine tumors
por: Paragliola, Rosa Maria, et al.
Publicado: (2016)

Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS)
por: Benavent, Marta, et al.
Publicado: (2021)

Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program
por: Sevilla, Isabel, et al.
Publicado: (2016)

An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs)
por: Alonso-Gordoa, Teresa, et al.
Publicado: (2015)

Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms
por: Laskaratos, Faidon-Marios, et al.
Publicado: (2019)

SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022)
por: Castillón, Jaume Capdevila, et al.
Publicado: (2023)

Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
por: Carmona-Bayonas, Alberto, et al.
Publicado: (2019)

Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide
por: Kos-Kudła, Beata, et al.
Publicado: (2017)

Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus
por: Sciammarella, Concetta, et al.
Publicado: (2020)

Management of incidentally discovered appendiceal neuroendocrine tumors after an appendicectomy
por: Muñoz de Nova, José Luis, et al.
Publicado: (2022)

Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development
por: Garcia-Carbonero, Rocio, et al.
Publicado: (2015)

Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies
por: Grande, Enrique, et al.
Publicado: (2012)

High-Dose Lanreotide in the Treatment of Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: A Case Report
por: Van Fraeyenhove, Frank, et al.
Publicado: (2014)

Long-Term Disease Control of a Pancreatic Neuroendocrine Tumor with Lanreotide Autogel(®): A Case Report
por: Lybaert, Willem, et al.
Publicado: (2014)

Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors
por: Saif, Muhammad Wasif, et al.
Publicado: (2018)

Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis
por: Ryan, P, et al.
Publicado: (2019)

Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors
por: Ito, Tetsuhide, et al.
Publicado: (2017)

Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
por: Capdevila, J., et al.
Publicado: (2023)

A significant response to sunitinib in a patient with anaplastic thyroid carcinoma
por: Grande, Enrique, et al.
Publicado: (2013)

Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly
por: Salvatori, Roberto, et al.
Publicado: (2009)

Long-Term Disease Control of a Non-Operable Neuroendocrine Tumor of the Lung with Lanreotide: A Case Study
por: Van Fraeyenhove, F., et al.
Publicado: (2012)

Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study
por: Caplin, Martyn E., et al.
Publicado: (2020)

Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria
por: Rinke, Anja, et al.
Publicado: (2021)

Pseudomyxoma Peritonei: Symptom Control and Objective Radiological Response after Treatment with Lanreotide Autogel
por: Zafra, Gema Marín, et al.
Publicado: (2016)

Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study
por: Paulson, Scott, et al.
Publicado: (2022)

Anomalous dynamics of water at the octopeptide lanreotide surface
por: Pinzan, Florian, et al.
Publicado: (2020)

Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
por: Adelman, Daphne T., et al.
Publicado: (2019)

Diabetes Insipidus Induced by Combination of Short-acting Octreotide and Lanreotide for Recurrent Carcinoid Crisis of Neuroendocrine Tumour: A Case Report
por: Guan, Goh Kian, et al.
Publicado: (2021)

Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial
por: Corti, Francesca, et al.
Publicado: (2023)

Approach to the Dynamic of Carbamazepine and its Main Metabolites in Soil Contamination through the Reuse of Wastewater and Sewage Sludge
por: Malvar, José Luis, et al.
Publicado: (2020)

A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features
por: Salazar, Ramon, et al.
Publicado: (2015)

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018)
por: González-Flores, E., et al.
Publicado: (2018)

Therapeutic options in the management of acromegaly: focus on lanreotide Autogel(®)
por: Roelfsema, Ferdinand, et al.
Publicado: (2008)

Atomic structure of Lanreotide nanotubes revealed by cryo-EM
por: Pieri, Laura, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o7nt7a4b6ff62vt98gtcgbruhd